Miyake Katsunori, Li Feng, Tezuka Yasuhiro, Awale Suresh, Kadota Shigetoshi
Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Nat Prod Commun. 2010 Jul;5(7):1009-12.
Twenty-four quassinoids isolated from Eurycoma longifolia Jack were investigated for their cytotoxicity against a panel of four different cancer cell lines, which includes three murine cell lines [colon 26-L5 carcinoma (colon 26-L5), B16-BL6 melanoma (B16-BL6), Lewis lung carcinoma (LLC)] and a human lung A549 adenocarcinoma (A549) cell line. Among the tested compounds, eurycomalactone (9) displayed the most potent activity against all the tested cell lines; colon 26-L5 (IC50 = 0.70 microM), B16-BL6 (IC50 = 0.59 microM), LLC (IC50 = 0.78 microM), and A549 (IC50 = 0.73 microM). These activities were comparable to clinically used anticancer agent doxorubicin (colon 26-L5, IC50 = 0.76 microM; B16-BL6, IC50 = 0.86 microM; LLC, IC50 = 0.80 microM; A549, IC50 = 0.66 microM).
对从长叶刺蒺藜中分离出的24种苦木素类化合物进行了研究，考察它们对一组四种不同癌细胞系的细胞毒性，这组细胞系包括三种鼠源细胞系[结肠26-L5癌（结肠26-L5）、B16-BL6黑色素瘤（B16-BL6）、Lewis肺癌（LLC）]和一种人肺A549腺癌（A549）细胞系。在测试的化合物中，刺蒺藜内酯（9）对所有测试细胞系表现出最强的活性；对结肠26-L5（IC50 = 0.70微摩尔）、B16-BL6（IC50 = 0.59微摩尔）、LLC（IC50 = 0.78微摩尔）和A549（IC50 = 0.73微摩尔）。这些活性与临床使用的抗癌药物阿霉素相当（结肠26-L5，IC50 = 0.76微摩尔；B16-BL6，IC50 = 0.86微摩尔；LLC，IC50 = 0.80微摩尔；A549，IC50 = 0.66微摩尔）。
